Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3047005 | 0.86 | ALDH1A1 (0.35) | FGFR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3046969 | 0.84 | DRD1 (0.35) | EGFRFGFR1 | |
| SCHEMBL3034828 | 0.82 | GFER (0.32) | FGFR1GFERKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3044219 | 0.81 | DRD1 (0.35) | EGFRFGFR1 | |
| SCHEMBL13137119 | 0.80 | HDAC1 (0.38) | FGFR1GFERKMT2AALDH1A1ALDH1A3 | |
| SCHEMBL6489900 | 0.78 | FGFR1 (0.45) | FGFR1KMT2AALDH1A1 | |
| SCHEMBL6489898 | 0.78 | FGFR1 (0.42) | FGFR1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3044292 | 0.78 | FGFR1 (0.36) | FGFR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3044301 | 0.76 | ALDH1A1 (0.34) | FGFR1GFERKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3054809 | 0.76 | KDM4E (0.36) | KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | EGFR 1277/4885FGFR1 2658/4885GFER 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.